Search - tctmd.com

Displaying 521 - 540 of 2134

Sort: Relevancy | Date

News Daily News

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

Yael L. Maxwell

June 30, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Daily News

New-Generation DES Work Just Fine in Women With Acute MI

Todd Neale

June 29, 2017

News Daily News

US Lawmakers Urged India to Rethink Stent Price Cap Ahead of State Visit

Shelley Wood

June 27, 2017

News Daily News

One in 10 TAVR Patients Treated Off-Label: TVT Registry

Michael O'Riordan

June 22, 2017

News Industry News

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

June 22, 2017

News Industry News

iVascular & Braile partner to develop structural heart solutions

June 19, 2017

News Daily News

Almost Half of US Operators Do Under 50 PCIs Per Year: Does It Matter?

Shelley Wood

June 15, 2017

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Featured Fellow

Ankur Kalra, MD

Yael L. Maxwell

May 26, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

Shelley Wood

May 19, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Industry News

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

May 18, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

Advertisement

Full Metal Jacket Approach Yields ‘Acceptable’ Long-term Outcomes in CTOs

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

New-Generation DES Work Just Fine in Women With Acute MI

US Lawmakers Urged India to Rethink Stent Price Cap Ahead of State Visit

One in 10 TAVR Patients Treated Off-Label: TVT Registry

TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon

iVascular & Braile partner to develop structural heart solutions

Almost Half of US Operators Do Under 50 PCIs Per Year: Does It Matter?

Use of DAPT Score Following PCI Validated in PRODIGY Study

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

TCTMD’s Top 10 Most Popular Stories for May 2017

Ankur Kalra, MD

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

Slimmest Stent to Date Looks Promising in Small Study

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content